Liraglutide is a pharmaceutical drug with a long-acting fatty acylated glucagon-like peptide-1 (GLP-1), which is classed as a carboxylic acid rference. Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetes, its half-life is approximately 11-15 hours making it appropriate for once-daily dosing. Enzyme is dipeptidyl peptidase 4
Liraglutide is an injectable glucagon-like peptide (GLP-1) receptor agonist. Which was approved in 2010 by the US FDA as a treatment for type 2 diabetes mellitus (T2DM) as Victoza, and more recently has been approved at a higher dose as Saxenda, for chronic weight management [2]? T2DM is one of the most prevalent metabolic disorders which are characterized by hyperglycemia due to the detection of insulin secretion or also insulin action. GLP-1 is a natural incretin hormone which is realized from intestinal L-cells in response to hormonal, neural and nutrient stimuli. As GLP-1 is used for the treatment of T2DM its half-life is approximately 11-15 hours, which is suitable for once-daily dosing.
Liraglutide is used with an eating routine as well as exercise program to regulate glucose levels in grown-ups with sort 2 diabetes (situation where the body does not use insulin typically and in this way is not able to regulate the amount of sugar in the blood) when different drugs did not regulate levels alright. Liraglutide is likewise used to diminish the danger of a heart assault, stroke, or passing in grown-ups with sort 2 diabetes mellitus and heart and vein illness. Liraglutide is not utilized to treat type 1 diabetes (condition in which the body does not deliver insulin and along these lines can’t control the measure of sugar in the blood) or diabetic ketoacidosis (a genuine condition that may create if high glucose isn’t dealt with).
Liraglutide is utilized alongside a lessened calorie diet and exercise intended to help individuals who are stout or who are overweight and have weight-related therapeutic issues to get in shape and to keep from recovering that weight. Liraglutide is not utilized to treat type 2 diabetes. Liraglutide is in a class of drugs called incretin mimetics. It works by helping the pancreas to discharge the appropriate measure of insulin when glucose levels are high. Insulin enables the move to sugar from the blood into other body tissues where it is utilized for vitality. Liraglutide infusion likewise moderates the exhausting of the stomach and may diminish hunger and cause weight reduction.
Over the period, individuals who have diabetes and high glucose can create genuine or dangerous intricacies, including coronary illness, stroke, kidney issues, nerve harm, and eye issues. Utilizing medication(s), rolling out a way of life improvements (e.g., diet, work out, stopping smoking), and routinely checking your glucose may deal with your diabetes and enhance your wellbeing. This treatment may likewise diminish your odds of showing some kindness assault, stroke, or different diabetes-related confusions, for example, kidney disappointment, nerve harm (numb, chilly legs or feet; diminished sexual capacity in people), eye issues, including changes or loss of vision, or gum sickness. Your specialist and other medicinal services suppliers will converse with you about the most ideal approach to deal with your diabetes.
Liraglutide injection comes as an answer (fluid) in a prefilled dosing pen to infuse subcutaneously (under the skin) in your stomach, thigh, or upper arm. It is normally infused once per day with or without sustenance. Utilize liraglutide infusion at around a similar time each day. Pursue the bearings on your solution mark deliberately, and ask your specialist or drug specialist to clarify any part you don’t get it. Utilize liraglutide infusion precisely as coordinated.
Irritation of your pancreas (pancreatitis): Quit utilizing Victoza® and call your social insurance supplier immediately on the off chance that you have serious torment in your stomach territory (midriff) that won’t leave, with or without heaving. You may feel the torment from your guts to your back.
Low glucose (hypoglycemia): The getting low glucose might be higher on the off chance that you utilize Victoza® with another drug that can cause low glucose, for example, a sulfonylurea or insulin. Signs and manifestations of low glucose may include: tipsiness or dazedness, obscured vision, uneasiness, peevishness or mindset changes, perspiring, slurred discourse, appetite, disarray or sluggishness, unsteadiness, shortcoming, migraine, quick heartbeat, and feeling jumpy.
Kidney issues (kidney disappointment): In individuals who have kidney issues, looseness of the bowels, queasiness, and retching may cause lost liquids (drying out), which may make kidney issues deteriorate.
Genuine unfavourably susceptible responses: Quit utilizing Victoza® and get medicinal assistance just on the off chance which one has any manifestations of a genuine unfavourably susceptible response such as swelling of your face, lips, tongue or throat, issues breathing or gulping, serious rash or tingling, swooning or feeling mixed up, or an exceptionally fast heartbeat.
Gallbladder issues: Gallbladder issues have occurred in a few people who take Victoza. Tell your medicinal services supplier immediately in the event that you get side effects of gallbladder issues which may incorporate torment justified or center upper stomach zone, fever, sickness, and retching, or your skin or the white piece of your eyes turns yellow.
Another investigation finds that diabetes tranquilize liraglutide prompts weight reduction by following up on a zone of the cerebrum that controls consideration and potentially making attractive nourishments less fulfilling. The researchers utilized immunohistochemistry to break down 22 human cerebrum tissue tests for the nearness of GLP-1 receptors, which are protein atoms that react to the GLP hormone’s signal. She said they found- – out of the blue – that GLP-1 is communicated in the human cerebrum. They supposedly observed proof of this articulation on neurons, or nerve cells, in the cerebral cortex of the forebrain, a region in charge of the higher idea.
The scientists played out the second report in 18 grown-ups with Type 2 diabetes. Participants received 17 days of either liraglutide, up to 1.8 milligrams, or a fake treatment (sham medication) in an arbitrary request. At that point following a three-week “washout” of no drug, similar members received 17 days of the contrary treatment. Members were unconscious which treatment they got.
On the 17th day of each of the treatments, participants experienced mind filtering with useful attractive reverberation imaging (fMRI). Amid fMRI, members saw pictures of different sustenance. In light of profoundly attractive nourishments, for example, cake, cakes, and singed sustenance, liraglutide diminished reward enactments in the cortex contrasted and pictures of less alluring nourishments, for example, organic products, vegetables and other low-calorie, low-fat nourishments.
The lowered activation implies that people on liraglutide find profoundly attractive sustenance less eye-catching and less remunerating than they ordinarily would without liraglutide,” Farr said. “Consequently, this drug may turn out to be better for weight reduction for individuals who will, in general, eat all the more high-fat sustenance as a reward, for example, when they are pushed. Our investigation recognizes neural focuses for more successful weight reduction therapeutics later on.
Liraglutide is a once-everyday injectable subsidiary of human incretin glucagon-like peptide-1 (GLP-1), for treatment of sort 2 diabetes or even obesity.
Type 2 diabetes: Liraglutide enhances regulation of blood glucose. It decreases feast related hyperglycemia (for a day after organization) by expanding insulin emission (just) when needed by expanding glucose levels, postponing gastric purging as well as stifling prandial glucagon secretion. As of 2017, it is vague in the event that they influence a man’s danger of death.
In like manner to different degrees with other GLP-1 receptor agonists, liraglutide has favorable circumstances over more conventional treatments for sort 2 diabetes:
Obesity: Liraglutide has been endorsed as an injectable extra to a diminished calorie diet and expanded physical movement for incessant weight administration in grown-up patients. The predetermined criteria are an underlying weight list (BMI) of 30 kg/m2 or more noteworthy (large), or 27 kg/m2 or more prominent (overweight), within the sight of something like one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidaemia). During late 2014, information was accounted for from SCALE™ Obesity and Prediabetes trial that is randomized, twofold visually impaired, fake treatment controlled, global preliminary in non-diabetic individuals with heftiness as well as non-diabetic individuals who are overweight with comorbidities. In this stage 3a preliminary, there were 3,731 members randomized to treatment using liraglutide 3 mg or fake treatment, both in the mix with eating regimen as well as exercise. The individuals who finished the 56-week preliminary accomplished a normal weight reduction of 9.2%, to be contrasted and a 3.5% decrease in the fake treatment group.
It is obscure if the weight reduction will be lasting. Hunger concealment might be transitory and craving may return regardless of whether one keeps on utilizing liraglutide following 56 weeks.
Pancreatitis concerns: A meeting at Johns Hopkins in 2013 announced a clearly factually noteworthy link between hospitalization for intense pancreatitis and earlier treatment with GLP-1 subordinates, (for example, eventide) and DPP-4 inhibitors, (for example, sitagliptin).[17] accordingly, the United States FDA and the European Medicines Agency directed a survey of every accessible datum in regards to the conceivable association between incretin mimetics and pancreatitis or pancreatic malignant growth. In joint 2014 letter to New England Journal of Medicine, the offices reasoned that “A pooled examination of information from 14,611 patients with sort 2 diabetes from 25 clinical preliminaries in sitagliptin database gave no convincing proof of an expanded danger of pancreatitis or pancreatic malignant growth” and “The two offices are at a consensus that statements concerning a causal link between incretin-based medications as well as pancreatitis or pancreatic disease, as communicated as of late in the logical writing and in media, are conflicting with the ebb and flow information [8]. The FDA and the EMA have not achieved the last end as of now with respect to such a causal relationship. In spite of the fact that the totality of information that has been looked into gives consolation, pancreatitis will keep on being viewed as a hazard related with such medications until the point that more information is accessible; the two organizations keep on researching this security signal.
Thyroid cancer concerns: At subjections eightfold more prominent than those utilized in people, liraglutide resulted a factually critical increment in thyroid tumors in rodents. The clinical importance of such discoveries is not known [9]. In clinical preliminaries, the rate of thyroid tumors in patients treated using liraglutide was 1.3 per 1000 patient-years (4 individuals) contrasted with 1.0 for every 1000 patients (1 individual) in examination gatherings. The sole individual in comparator gathering and four of five people within the liraglutide bunch had serum markers (hoisted calcitonin) suggestive of prior ailment at baseline. The FDA said serum calcitonin, a biomarker of medullary thyroid malignancy, was marginally expanded in liraglutide patients, yet at the same time inside typical reaches, and it required continuous observing for a long time in a disease library.
Liraglutide is a once every day injectable treatment that demonstrations to assist individuals with Type 2 diabetes accomplish great glycaemic control by animating the arrival of insulin when glucose levels get too high and furthermore lessens craving.
NICE has now endorsed Liraglutide 1.2mg once-everyday as a significant treatment alternative for individuals with Type 2 diabetes as double or triple treatment with an oral treatment.
NICE direction stipulates that medications should just be preceded if blood glucose levels lessen inside a half year and those experiencing triple treatment figures out how to lose three percent of their underlying body weight.
NICE suggests considering pharmacological treatment simply after dietary, practice and social methodologies have been begun and assessed.
The rule prescribes to consider pharmacological treatment for individuals who have not achieved their objective weight reduction or have achieved a level on dietary, movement and conduct changes.
References
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017 Jan 1;40(Supplement 1): S64-74
Astrup A, Fujioka K, Greenway F, Lau DC, Van LG, Ortiz RV, Wilding JP, Skjøth TV, Manning LS, Pi-Sunyer X. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet (London, England). 2017 Apr;389(10077):1399-409
Bansal N. Prediabetes diagnosis and treatment: A review. World journal of diabetes. 2015 Mar 15;6(2):296
Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syrén A, Umpierrez GE. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016 Feb 1;39(2):222-30
Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, Albornoz C, Moreno C, Cepeda M, Almodóvar F. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes. BMC endocrine disorders. 2015 Dec;15(1):78
Jensterle M, Kravos NA, Gori?ar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in the treatment of obese PCOS: a randomized trial. BMC endocrine disorders. 2017 Dec;17(1):5
Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez AA. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015 Mar;14(1):81-90
Larsen JR, Vedtofte L, Jakobsen MS, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. Jama Psychiatry. 2017 Jul 1;74(7):719-28
Ma Z, Chen R, Liu Y, Yu P, Chen L. Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes. International journal of clinical pharmacology and therapeutics. 2015 Nov;53(11):933-9
Matza LS, Boye KS, Currie BM, Paczkowski R, Lando LF, Mody R, Jordan J. Patient perceptions of injection devices used with dulaglutide and liraglutide for the treatment of Type 2 diabetes. Current medical research and opinion. 2018 May 11:1-8
O’Neil PM, Aroda VR, Astrup A, Kushner R, Lau DC, Wadden TA, Brett J, Cancino AP, Wilding JP, Satiety and Clinical Adiposity–Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes, Obesity, and Metabolism. 2017 Nov; 19(11):1529-36
Orr ME, Sullivan AC, Frost B. A brief overview of tauopathy: causes, consequences, and therapeutic strategies. Trends in pharmacological sciences. 2017 Jul 1; 38(7):637-48
Terlizzese P, Losurdo F, Iacoviello M, Aspromonte N. Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. Heart failure reviews. 2018 May 1; 23(3):469-79
Vilsbøll T, Knop FK. Therapy: Liraglutide—preventing or postponing T2DM diagnosis? Nature Reviews Endocrinology. 2017 Jun;13(6):320
Essay Writing Service Features
Our Experience
No matter how complex your assignment is, we can find the right professional for your specific task. Contact Essay is an essay writing company that hires only the smartest minds to help you with your projects. Our expertise allows us to provide students with high-quality academic writing, editing & proofreading services.
Free Features
Free revision policy
$10Free bibliography & reference
$8Free title page
$8Free formatting
$8How Our Essay Writing Service Works
First, you will need to complete an order form. It's not difficult but, in case there is anything you find not to be clear, you may always call us so that we can guide you through it. On the order form, you will need to include some basic information concerning your order: subject, topic, number of pages, etc. We also encourage our clients to upload any relevant information or sources that will help.
Complete the order form
Once we have all the information and instructions that we need, we select the most suitable writer for your assignment. While everything seems to be clear, the writer, who has complete knowledge of the subject, may need clarification from you. It is at that point that you would receive a call or email from us.
Writer’s assignment
As soon as the writer has finished, it will be delivered both to the website and to your email address so that you will not miss it. If your deadline is close at hand, we will place a call to you to make sure that you receive the paper on time.
Completing the order and download
